or
forgot password

A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma


Phase 2
18 Years
N/A
Not Enrolling
Both
Renal Cell Cancer

Thank you

Trial Information

A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma

Inclusion Criteria


Inclusion Criteria

- Renal Cell Carcinoma.

- Recurrent tumor.

- At least 6 weeks post-nephrectomy.

- Able to tolerate normal activities of daily living.

- Adequate bone marrow, kidney, and liver function.

Exclusion Criteria

- Pregnant or breast feeding.

- Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.

- CNS metastasis.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective Response Rate in subjects with RCC

Outcome Time Frame:

1 year

Principal Investigator

Helen Eliopoulos, M.D.

Investigator Role:

Study Director

Investigator Affiliation:

Abbott

Authority:

United States: Food and Drug Administration

Study ID:

M02-416

NCT ID:

NCT00073112

Start Date:

August 2003

Completion Date:

September 2006

Related Keywords:

  • Renal Cell Cancer
  • Carcinoma, Renal Cell
  • Colorectal Neoplasms

Name

Location
UCLA School of Medicine Los Angeles, California  900121973
West Cancer Clinic Memphis, Tennessee  38120
University of Chicago Medical Center Chicago, Illinois  60637
Oncology Hematology Group of South Florida Miami, Florida  33176
Vanderbilt Ingram Cancer Center Nashville, Tennessee  37232
Sidney Kimmel Comprehensive Cancer Center Lutherville, Maryland  
Arizona Cancer Research Center Tucson, Arizona  85712
Clinical Trials + Research Associates Montebello, California  90640
US Oncology Inc Rocky Mountain Cancer Centers Denver, Colorado  80218
US Oncology Inc Florida Cancer Institute New Port Richey, Florida  34652
US Oncology Inc Ocala Oncology Center Ocala, Florida  34474
US Oncology Inc Cancer Centers of Florida, P.A. Orlando, Florida  32806
US Oncology Inc Raleigh Hematology Oncology Clinic Cary, North Carolina  27511
US Oncology Inc Dayton Oncology & Hematology P.A. Kettering, Ohio  45409
US Oncology Inc Cancer Care Accociates-Mercy Campus Oklahoma City, Oklahoma  73120
US Oncology Inc Cancer Centers of the Carolinas Greenville, South Carolina  29615
US Oncology Inc Tyler Cancer Center Tyler, Texas  75702
US Oncology Inc Cancer Care Northwest-North Spokane, Washington  99218
US Oncology Inc Northwest Cancer Specialists Vancouver, Washington  98684